Related Experiment Video

Updated: Jun 5, 2026

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

Notch pathway inhibition significantly reduces rhabdomyosarcoma invasiveness and mobility in vitro

Josep Roma1, Anna Masià, Jaume Reventós

  • 1Biomedical Research Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|December 24, 2010
PubMed
Abstract

Insights

Inhibiting the Notch pathway significantly reduced the mobility and invasiveness of rhabdomyosarcoma (RMS) cells, suggesting its role in cancer metastasis. This finding offers potential therapeutic targets for this pediatric soft tissue sarcoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pediatric Malignancies

Background:

  • Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma.
  • Metastatic RMS has a poor prognosis, with high rates of recurrence in advanced disease.
  • The Notch pathway is implicated in various cancers, including some pediatric malignancies.

Purpose of the Study:

  • To investigate the role of the Notch pathway in rhabdomyosarcoma.
  • To evaluate the effects of Notch pathway inhibition on RMS cell behavior.

Main Methods:

  • Real-time PCR was used to assess Notch pathway component expression in RMS cell lines.
  • Four gamma-secretase inhibitors (GSIs) and dominant-negative MAML1 were used to inhibit the Notch pathway.
  • Cellular assays included wound-healing, invasion, cell-cycle, and apoptosis analyses.

Main Results:

  • The Notch pathway was widely expressed and activated in RMS.
  • Inhibition of the Notch pathway with GSIs or MAML1 significantly reduced RMS cell mobility and invasiveness.
  • Notch pathway inhibition did not affect RMS cell cycle progression or apoptosis.

Conclusions:

  • Pharmacological or genetic blockade of the Notch pathway reduces RMS cell invasiveness.
  • The Notch pathway plays a role in regulating the metastatic potential of rhabdomyosarcoma.
  • Targeting the Notch pathway may offer a therapeutic strategy for metastatic RMS.

Related Concept Videos

Notch Signaling Pathway03:14

Notch Signaling Pathway

The Notch signaling pathway is a major intracellular signaling pathway that is highly conserved over a broad spectrum of metazoan species. It stands unique from other intracellular signaling mechanisms in animals because notch protein itself acts as the receptor as well as the primary signaling molecule.
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
Notch Signaling Pathway03:14

Notch Signaling Pathway

The Notch signaling pathway is a major intracellular signaling pathway that is highly conserved over a broad spectrum of metazoan species. It stands unique from other intracellular signaling mechanisms in animals because notch protein itself acts as the receptor as well as the primary signaling molecule.
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
Role Of Notch Signalling In Intestinal Stem Cell Renewal01:12

Role Of Notch Signalling In Intestinal Stem Cell Renewal

Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However, invadopodia can...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...